HCV is a popular disease, and about millions infected patients in Asia. According to GDMeds, https://gdmeds.com/. Sale data, lots of them are located in China, India, and xxx… Today’s direct-acting antiviral (DAA) treatments (https://gdmeds.com/?s=sofosbuvir&post_type=product) for hepatitis C are highly effective. The standard course of eight or 12 weeks of daily medication puts your chances of…
Heads up from GDMeds pharmacy, The Asia and Pacific region was home to an estimated 5.8 million people living with HIV in 2019.1 China, India and Indonesia account for almost three-quarters of the total number of people living with HIV in the region.2 It is increasingly clear that the Asia and Pacific region is…
As a pharmacy and the distributor of anti-COVID-19 medicines, e.g. Remdesivir, Alltera, etc. GDMeds works on the frontline, and wish could support most people get necessary medicines and overcome this pandemic. As the pandemic rages on, it’s increasingly clear that widespread vaccination is essential to help contain it. Physical distancing, universal face coverings, and frequent…
State health departments were most likely to refer heterosexual adults for HIV preexposure prophylaxis (PrEP) appointments and least likely to refer transgender and Black adults, according to the results of a 12-city PrEP demonstration project. The project, Project PrIDE, was meant to close the PrEP gap between White and cisgender adults and their Black, Latinx, Native American, and transgender…
The malaria drug hydroxychloroquine failed to protect healthcare workers caring for COVID-19 patients from becoming infected themselves, according to results of a formal, placebo-controlled trial published in Clinical Infectious Diseases. The 1,483 participants worked in emergency departments, intensive care units, and other high-risk sites in the United States and the Canadian province of Manitoba. They…
The US Food and Drug Administration (FDA) has added 25 drugs or drug classes to its quarterly list of agents in which it has found a potential sign of serious risk or new safety information. The new list, created from the FDA Adverse Event Reporting System (FAERS), covers April through June, and is current as of October…
